A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril-valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF).

Trial Profile

A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril-valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Enalapril
  • Indications Decompensated heart failure
  • Focus Therapeutic Use
  • Acronyms PIONEER-HF
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 16 Oct 2017 Planned End Date changed from 5 Apr 2018 to 29 Jun 2018.
    • 16 Oct 2017 Planned primary completion date changed from 5 Apr 2018 to 29 Jun 2018.
    • 05 Oct 2017 Planned End Date changed from 1 Apr 2018 to 5 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top